Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Launch of 20 new medicines expected by 2030
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Subscribe To Our Newsletter & Stay Updated
